Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases

被引:0
|
作者
Perumal, Sathish Kumar [1 ,2 ]
Arumugam, Madan Kumar [1 ,2 ,3 ]
Osna, Natalia A. [4 ]
Rasineni, Karuna [5 ]
Kharbanda, Kusum K. [1 ,2 ,5 ]
机构
[1] Nebraska Western Iowa Hlth Care Syst, Dept Vet Affairs, Res Serv, Omaha, NE 68803 USA
[2] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
[3] Sathyabama Inst Sci & Technol, Ctr Mol & Nanomed Sci, Canc Biol Lab, Chennai, Tamil Nadu, India
[4] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
[5] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
来源
FRONTIERS IN NUTRITION | 2025年 / 12卷
关键词
betaine; liver; alcohol-associated liver disease; metabolic dysfunction-associated steatotic liver disease; gut-liver axis; intestinal barrier integrity; gut microbiome; NONALCOHOLIC FATTY LIVER; INCREASED INTESTINAL PERMEABILITY; HOMOCYSTEINE METHYLTRANSFERASE BHMT; ELEVATED S-ADENOSYLHOMOCYSTEINE; ALCOHOL-INDUCED ENDOTOXEMIA; CHRONIC ETHANOL-CONSUMPTION; HEPATIC LIPID-ACCUMULATION; CACO-2 CELL MONOLAYERS; RECEPTOR; EXPRESSION; TIGHT JUNCTIONS;
D O I
10.3389/fnut.2025.1478542
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Chronic liver disease is defined by persistent harm to the liver that might result in decreased liver function. The two prevalent chronic liver diseases are alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). There is ample evidence that the pathogenesis of these two chronic liver diseases is closely linked to gastrointestinal dysfunctions that alters the gut-liver crosstalk. These alterations are mediated through the imbalances in the gut microbiota composition/function that combined with disruption in the gut barrier integrity allows for harmful gut microbes and their toxins to enter the portal circulation and reach the liver to elicit an inflammatory response. This leads to further recruitment of systemic inflammatory cells, such as neutrophils, T-cells, and monocytes into the liver, which perpetuate additional inflammation and the development of progressive liver damage. Many therapeutic modalities, currently used to prevent, attenuate, or treat chronic liver diseases are aimed at modulating gut dysbiosis and improving intestinal barrier function. Betaine is a choline-derived metabolite and a methyl group donor with antioxidant, anti-inflammatory and osmoprotectant properties. Studies have shown that low betaine levels are associated with higher levels of organ damage. There have been several publications demonstrating the role of betaine supplementation in preventing the development of ALD and MASLD. This review explores the protective effects of betaine through its role as a methyl donor and its capacity to regulate the protective gut microbiota and maintain intestinal barrier integrity to prevent the development of these chronic liver diseases. Further studies are needed to enhance our understanding of its therapeutic potential that could pave the way for targeted interventions in the management of not only chronic liver diseases, but other inflammatory bowel diseases or systemic inflammatory conditions.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Gut-liver axis signaling in portal hypertension
    Benedikt Simbrunner
    Mattias Mandorfer
    Michael Trauner
    Thomas Reiberger
    World Journal of Gastroenterology, 2019, 25 (39) : 5897 - 5917
  • [42] Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg
    Arab, Juan P.
    Martin-Mateos, Rosa M.
    Shah, Vijay H.
    HEPATOLOGY INTERNATIONAL, 2018, 12 : S24 - S33
  • [43] Lentinan Supplementation Protects the Gut-Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved
    Yang, Xiaoying
    Zheng, Mingxuan
    Zhou, Menglu
    Zhou, Limian
    Ge, Xing
    Pang, Ning
    Li, Hongchun
    Li, Xiangyang
    Li, Mengdi
    Zhang, Jun
    Huang, Xu-Feng
    Zheng, Kuiyang
    Yu, Yinghua
    FRONTIERS IN NUTRITION, 2022, 8
  • [44] Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease
    Paolella, Giulia
    Mandato, Claudia
    Pierri, Luca
    Poeta, Marco
    Di Stasi, Martina
    Vajro, Pietro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15518 - 15531
  • [45] Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies
    Frasinariu, Otilia E.
    Ceccarelli, Sara
    Alisi, Anna
    Moraru, Evelina
    Nobili, Valerio
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (07) : 543 - 551
  • [46] Examining the gut-liver axis in liver cancer using organoid models
    Shek, Dmitrii
    Chen, Dishen
    Read, Scott A.
    Ahlenstiel, Golo
    CANCER LETTERS, 2021, 510 : 48 - 58
  • [47] Galangin alleviates alcoholic liver disease by regulating the gut-liver axis
    Duan, Dongzhu
    Du, Zhenzhen
    Zhao, Ling
    JOURNAL OF FUNCTIONAL FOODS, 2024, 122
  • [48] Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis
    Liu, Qiu-Luo
    Zhou, Huijie
    Wang, Ziqiang
    Chen, Yan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2025, 13
  • [49] Maslinic acid alleviates alcoholic liver injury in mice and regulates intestinal microbiota via the gut-liver axis
    Su, Jingwen
    Dai, Yuan
    Wu, Xianyao
    Zhou, Xinhu
    Fang, Xianying
    Ge, Xiangyang
    Zhao, Linguo
    JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 2024, 104 (13) : 7928 - 7938
  • [50] Intestinal ischemia and the gut-liver axis:: An in vitro model
    Towfigh, S
    Heisler, T
    Rigberg, DA
    Hines, OJ
    Chu, J
    McFadden, DW
    Chandler, C
    JOURNAL OF SURGICAL RESEARCH, 2000, 88 (02) : 160 - 164